By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


GW Pharmaceuticals Ltd. 

Porton Down Science Park

Salisbury  Wiltshire  SP4 0JQ  United Kingdom
Phone: 44-1980-619000 Fax: +44-1980-619111



Company News
GW Pharmaceuticals (GWPH) Receives Orphan Drug Designation From FDA For Cannabidiol For The Treatment Of Neonatal Hypoxic-Ischemic Encephalopathy 4/24/2015 7:33:48 AM
GW Pharmaceuticals (GWPH) Announces New Physician Reports Of Epidiolex Treatment Effect In Children And Young Adults With Treatment-Resistant Epilepsy 4/23/2015 10:43:28 AM
GW Pharmaceuticals (GWPH) Initiates Second Phase 3 Pivotal Trial For Epidiolex In Dravet Syndrome 4/21/2015 7:39:57 AM
GW Pharmaceuticals (GWPH) Notes New Epidiolex Data Released By The American Academy of Neurology 4/14/2015 7:47:33 AM
GW Pharmaceuticals (GWPH) Initiates First Phase 3 Pivotal Trial For Epidiolex In Dravet Syndrome 3/31/2015 6:38:26 AM
GW Pharmaceuticals (GWPH) To Present At Upcoming Investor Conferences 2/25/2015 7:59:48 AM
GW Pharmaceuticals (GWPH) To Present At The Leerink 2015 Global Healthcare Conference 2/5/2015 1:21:44 PM
GW Pharmaceuticals (GWPH) Reports First Quarter 2015 Financial Results And Operational Progress 2/4/2015 10:12:12 AM
GW Pharmaceuticals (GWPH) To Report Q1, 2015 Financial Results And Host Conference Call On 4 February, 2015 1/27/2015 7:33:45 AM
GW Pharmaceuticals (GWPH) And Otsuka Pharmaceutical Co., Ltd. Announce Results In First Of Three Sativex® Phase 3 Cancer Pain Trials 1/8/2015 8:34:21 AM